1308|715|Public
5|$|As of 2017, several disease-modifying {{treatments}} {{have been}} approved by regulatory agencies of different countries, including the U.S. Food and Drug Administration (FDA), the <b>European</b> <b>Medicines</b> <b>Agency</b> (EMEA) and the Pharmaceuticals and Medical Devices Agency (PMDA) of the Japanese Ministry of Health, Labour and Welfare.|$|E
5|$|In 2011, the <b>European</b> <b>Medicines</b> <b>Agency</b> {{granted a}} {{marketing}} authorisation for a buccal application form of midazolam, sold under the trade name Buccolam. Buccolam was approved {{for the treatment}} of prolonged, acute, convulsive seizures in people from three months to less than 18 years of age. This was the first application of a paediatric-use marketing authorisation.|$|E
5|$|Further {{evidence}} of the scientific consensus includes the rejection of a causal link between thiomersal and autism by multiple national and international scientific and medical bodies including the American Medical Association, the American Academy of Pediatrics, the American College of Medical Toxicology, the Canadian Paediatric Society, the U.S. National Academy of Sciences, the Food and Drug Administration, Centers for Disease Control and Prevention, the World Health Organization, the Public Health Agency of Canada, and the <b>European</b> <b>Medicines</b> <b>Agency.</b>|$|E
5000|$|<b>European</b> <b>Medicines</b> <b>Agency’s</b> (EMA) {{scientific}} guidelines on biostatistics ...|$|R
50|$|The Committee on Herbal Medicinal Products (HMPC), is the <b>European</b> <b>Medicines</b> <b>Agency's</b> {{committee}} {{responsible for}} elaborating the agency's opinions on herbal medicines.|$|R
5000|$|In Jan 2015 the <b>European</b> <b>Medicines</b> <b>Agency's</b> (EMA) Committee for Orphan Medical Products (COMP) gave a {{positive}} review of enadenotucirev to treat platinum-resistant ovarian cancer.|$|R
25|$|On 21 January 2009, the <b>European</b> <b>Medicines</b> <b>Agency</b> granted {{approval}} {{for the sale of}} orlistat without a prescription.|$|E
25|$|<b>European</b> <b>Medicines</b> <b>Agency</b> {{recommended}} {{suspension of}} marketing authorisations for meprobamate-containing medicines in the European Union in January 2012.|$|E
25|$|On January 21, 2010, the <b>European</b> <b>Medicines</b> <b>Agency</b> {{recommended}} {{suspension of}} marketing authorizations for sibutramine {{based on the}} SCOUT study results.|$|E
50|$|The company’s {{products}} are manufactured at mammalian cell culture facilities {{designed and built}} {{to comply with the}} United States FDA’s cGMP, and the <b>European</b> <b>Medicines</b> <b>Agency’s</b> GMP standards.|$|R
50|$|The Committee for Medicinal Products for Human Use (CHMP), {{formerly}} known as Committee for Proprietary Medicinal Products (CPMP), is the <b>European</b> <b>Medicines</b> <b>Agency's</b> committee responsible for elaborating the agency's opinions on all issues regarding medicinal products for human use.|$|R
50|$|On November 21, 2008, the <b>European</b> <b>Medicines</b> <b>Agency’s</b> (EMEA) Committee for Medicinal Products for Human Use (CHMP) {{adopted a}} {{positive}} opinion for ustekinumab {{for the treatment}} of moderate to severe plaque psoriasis in adult patients who failed to respond to other systemic therapies.|$|R
25|$|In 2015, the <b>European</b> <b>Medicines</b> <b>Agency</b> (EMA) {{announced}} {{a small but}} definite risk of QT prolongation {{associated with the use}} of hydroxyzine.|$|E
25|$|The <b>European</b> <b>Medicines</b> <b>Agency</b> {{has advised}} that for pneumonia, acute {{bacterial}} sinusitis, and acute exacerbations of COPD, it {{should only be}} used when other antibiotics are inappropriate.|$|E
25|$|On September 20, 2011, the <b>European</b> <b>Medicines</b> <b>Agency</b> (EMA) granted HPbCD {{orphan drug}} status and {{designated}} the compound {{as a potential}} treatment for Niemann–Pick type C disease.|$|E
40|$|The <b>European</b> <b>Medicine</b> <b>Agency</b> grants {{marketing}} {{of drugs in}} all Europe, regulatory agency of each country can register the drug, but can also deny public reimbursement thus restricting the options of the oncologist. The European Oncology Associations should join to their effort to achieve a uniform access to the cancer therapy for all patients in Europe...|$|R
30|$|Cancer {{had never}} been {{considered}} as a relevant problem in patients treated with lithium until 2015, when a document published by the <b>European</b> <b>Medicine</b> <b>Agency</b> concluded that long-term use of lithium might induce renal tumors. A few months later, we observed {{the case of a}} woman treated with lithium for 18  years who was diagnosed with both thyroid and renal tumors.|$|R
50|$|In 2013 the <b>European</b> <b>Medicines</b> <b>Agency’s</b> Committee for Medicinal Products for Human Use (CHMP) has {{recommended}} that medicines containing ergot derivatives {{no longer be}} used to treat several conditions involving problems with memory, sensation or blood circulation, or to prevent migraine headaches because the risks (increased risk of fibrosis and ergotism) {{were said to be}} greater than the benefits in these indications.|$|R
25|$|The use of {{chlorpromazine}} in food-producing {{animals is}} not permitted in the EU, as a maximum residue limit {{could not be}} determined following assessment by the <b>European</b> <b>Medicines</b> <b>Agency.</b>|$|E
25|$|In 2006 it was {{approved}} {{for the treatment}} of MM along with dexamethasone and in 2007 by <b>European</b> <b>Medicines</b> <b>Agency</b> (EMA). In 2008, phase II trial observed efficacy in treating Non-Hodgkin's lymphoma.|$|E
25|$|Health Canada and the US Food and Drug Administration (FDA) have {{approved}} pregabalin and duloxetine, {{for the management}} of fibromyalgia. The FDA also approved milnacipran, but the <b>European</b> <b>Medicines</b> <b>Agency</b> refused marketing authority.|$|E
5000|$|In contrast, the <b>European</b> <b>Medicines</b> <b>Agency's</b> 2012 [...] "Assesment {{report for}} Pholcodine {{containing}} medicinal products" [...] concludes this: The Committee considered that {{evidence of an}} association between pholcodine use and development ofNMBA-related anaphylaxis is circumstantial, not entirely consistent and therefore does not support theconclusion {{that there is a}} significant risk of cross-sensitisation to NMBAs and subsequent developmentof anaphylaxis during surgery.|$|R
25|$|In June 2013, two biosimilar {{versions}} (Inflectra and Remsima) {{were submitted}} for approval in Europe, by Hospira and Celltrion Healthcare respectively. Both {{had a positive}} opinion from <b>European</b> <b>Medicines</b> <b>Agency’s</b> (EMA) Committee for Medicinal Products for Human Use (CHMP) {{for sale in the}} European Union (EU). Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by Sept 2013.|$|R
40|$|In February 2009, the <b>European</b> <b>Medicines</b> <b>Agency's</b> (EMEA) Committee for Medicinal Products for Human Use (CHMP) had {{recommended}} {{the suspension of}} efalizumab's (Raptiva) marketing authorization, because its benefits {{in the treatment of}} psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly...|$|R
25|$|A recent {{evaluation}} {{from the}} <b>European</b> <b>Medicines</b> <b>Agency</b> (EMA) {{concluded that the}} overall benefit/risk profile of nimesulide is favourable and in line {{with that of the}} other NSAIDs such as diclofenac, ibuprofen, and naproxen.|$|E
25|$|In 2011, the <b>European</b> <b>Medicines</b> <b>Agency</b> {{approved}} Tafamidis or Vyndaqel for the amelioration of FAP. Vyndaqel kinetically stabilizes the TTR tetramer, preventing tetramer dissociation {{required for}} TTR amyloidogenesis and {{degradation of the}} autonomic nervous system and/or the peripheral nervous system and/or the heart.|$|E
25|$|Due {{to reports}} of adverse {{withdrawal}} reactions upon terminating treatment, the Committee for Medicinal Products for Human Use (CHMP) at the <b>European</b> <b>Medicines</b> <b>Agency</b> recommends gradually reducing over several {{weeks or months}} if the decision to withdraw is made. See also Discontinuation syndrome (withdrawal).|$|E
50|$|In June 2013, two biosimilar {{versions}} (Inflectra and Remsima) {{were submitted}} for approval in Europe, by Hospira and Celltrion Healthcare respectively. Both {{had a positive}} opinion from <b>European</b> <b>Medicines</b> <b>Agency’s</b> (EMA) Committee for Medicinal Products for Human Use (CHMP) {{for sale in the}} European Union (EU). Celltrion obtained marketing authorization approval (MAA) from 27 EU countries and 3 EEA (European Economic Area) countries by Sept 2013.|$|R
2500|$|The less toxic and {{generally}} more effective triazole antifungal agents fluconazole and itraconazole are usually preferred for systemic use. In 2013 the <b>European</b> <b>Medicines</b> <b>Agency's</b> Committee on Medicinal Products for Human Use (CHMP) recommended that a ban {{be imposed on}} the use of oral ketoconazole for systemic use in humans throughout the European Union, after concluding that the risk of serious liver injury from systemic ketoconazole outweighs its benefits. [...] The oral formulation of ketoconazole was discontinued in Australia in 2013 and in China in 2015.|$|R
50|$|An eCTD submission's {{structure}} is largely {{defined by the}} primary standard created by the ICH, the Electronic Common Technical Document Specification. However, additional specifications may be applied in national and continental contexts. In the United States, the Food and Drug Administration (FDA) layers additional specifications onto its requirements for eCTD submissions, including PDF, transmission, file format, and supportive file specifications. In the European Union, the <b>European</b> <b>Medicines</b> <b>Agency's</b> EU Module 1 specification {{as well as other}} QA documents lay out additional requiremements for eCTD submissions.|$|R
25|$|Liraglutide, a once-daily human {{analogue}} (97% homology), {{has been}} developed by Novo Nordisk under the brand name Victoza. The product {{was approved by the}} <b>European</b> <b>Medicines</b> <b>Agency</b> (EMEA) on July 3, 2009, and by the U.S. Food and Drug Administration (FDA) on January 25, 2010.|$|E
25|$|T-vec was {{approved}} by the U.S. Food and Drug Administration to treat melanoma in October 2015. It was the first approval of an oncolytic virus in the West. It was provisionally approved by the <b>European</b> <b>Medicines</b> <b>Agency</b> in December of that year – continued marketing approval depended on further clinical results.|$|E
25|$|Azacitidine {{is a drug}} used {{to treat}} CMML and is {{approved}} by the Food and Drug Administration (FDA) and the <b>European</b> <b>Medicines</b> <b>Agency.</b> Stem cell transplant {{is also used to}} treat CMML, and involves the transplantation of donor haematopoietic stem cells into the recipient. Blood transfusion and erythropoietin are used to treat disease associated anaemia.|$|E
50|$|Companies {{that want}} to {{manufacture}} generic drugs must show in their applications to the FDA that they guarantee quality and bioequivalence. In July 2016, the FDA generic drug application backlog comprised 4,036 generics. On the other hand, the <b>European</b> <b>Medicine</b> <b>Agency</b> (EMA), Europe's equivalent to the FDA, had only 24 generics drug applications awaiting approval. This count includes biologically based biosimilars awaiting approval. The FDA's generic count doesn't include biosimilars, which are more complicated medicines to review. According to Generic Pharmaceutical Association, the median time it takes for the FDA to approve a generic is 47 months.|$|R
40|$|Several {{studies have}} {{demonstrated}} {{the efficacy of the}} oral pre-exposure prophylaxis (PrEP) with tenofovir (with or without emtricitabine) on preventing HIV-negative partners of HIV infected patients to become infected through sexual contacts. PrEP is already available in the United States and now is approved by <b>European</b> <b>Medicine</b> <b>Agency.</b> In this setting we would like to gauge physiciansâ 8 ̆ 09 ̆ 9 knowledge, acquaintance with and attitude to include PrEP in their clinical practice. A cross sectional survey was conducted among Italian physicians expert on antiretroviral therapy. Out of 146 physicians, 35...|$|R
40|$|In the EU, a {{medicinal}} product needs a marketing authorization (MA) {{to be placed}} on the market. The EU's {{medicinal product}}s'legislative framework allows for a reduced application for medicines outside their data exclusivity. One such type of application is the well-established use (WEU) medicinal product application. Recently, these MA applications have been subject to arbitration procedures at the <b>European</b> <b>Medicines</b> <b>Agency's</b> Committee for Medicinal Products for Human Use (CHMP) because of disagreements between member states during the authorisation process. This paper reflects on these cases and highlights their potential impact on future WEU applications...|$|R
